Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
11%
Ph phase_1
7
78%
Ph not_applicable
1
11%

Phase Distribution

8

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
7(77.8%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(8)

Detailed Status

Completed8
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (11.1%)
Phase 17 (77.8%)
N/A1 (11.1%)

Trials by Status

not_yet_recruiting111%
completed889%

Recent Activity

0 active trials
Showing 5 of 9
not_yet_recruitingearly_phase_1

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

NCT07090538
completedphase_1

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

NCT06188325
completedphase_1

A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth

NCT06193304
completedphase_1

GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

NCT04944888
completednot_applicable

Eliglustat on Gaucher Disease Type IIIB

NCT03519646
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07090538Early Phase 1

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

Not Yet Recruiting
NCT06188325Phase 1

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

Completed
NCT06193304Phase 1

A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth

Completed
NCT04944888Phase 1

GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

Completed
NCT03519646Not Applicable

Eliglustat on Gaucher Disease Type IIIB

Completed
NCT02536937Phase 1

A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

Completed
NCT02536911Phase 1

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

Completed
NCT02422654Phase 1

Taste Evaluation of Different Liquid Formulations With Eliglustat

Completed
NCT01659944Phase 1

Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9